Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a range of recombinant antibodies targeting CLDN6, crafted to address the varying needs of biomedical researchers and institutions. Utilizing cutting-edge technology, these antibodies ensure superior specificity and consistent performance across diverse applications. With a focus on advancing scientific discovery, these tools provide valuable support in the investigation of CLDN6's role in both health and disease. Choose Creative Biolabs to enhance your research with our innovative recombinant antibody offerings.
CLDN6 (Claudin 6) is a tight junction protein. It has emerged as an important target in biomedical research. CLDN6 is often overexpressed in certain cancers, making it a potential target for cancer therapy. Research on CLDN6 can help in understanding the mechanisms of cancer development and progression. By targeting CLDN6, researchers may be able to develop novel therapeutic strategies for cancer treatment, such as targeted drugs or immunotherapies. Additionally, studying CLDN6 may also provide insights into normal physiological processes involving tight junctions and cell adhesion.
claudin 6
Tight junctions represent one mode of cell-to-cell adhesion in epithelial or endothelial cell sheets, forming continuous seals around cells and serving as a physical barrier to prevent solutes and water from passing freely through the paracellular space.
Intracellular, Membrane (different isoforms)
Cell type enhanced (Extravillous trophoblasts, Syncytiotrophoblasts, Cytotrophoblasts, Ductal cells)
Not detected in immune cells
Group enriched (BEWO, CACO-2, NTERA-2, SuSa)
Directly interacts with TJP1/ZO-1, TJP2/ZO-2 and TJP3/ZO-3 (By similarity). Interacts with CLDN1, CD81 and OCLN (PubMed:20375010).
Host cell receptor for virus entry, Receptor
Our premium recombinant antibodies targeting CLDN6 are designed to accelerate research and facilitate the discovery of therapeutic agents related to this crucial target.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-510LC | Mouse Anti-CLDN6 Recombinant Antibody | Human | Mouse | Cyt; FC; FuncS |
TAB-507LC | Mouse Anti-CLDN6 Recombinant Antibody | Human | Mouse | Cyt; FC; FuncS |
HPAB-0078-FY | Mouse Anti-CLDN6 Recombinant Antibody | Human | Mouse | Active |
HPAB-1496-FY | Mouse Anti-CLDN6 Recombinant Antibody | Human | Mouse | ELISA; FC |
HPAB-1497-FY | Mouse Anti-CLDN6 Recombinant Antibody | Human | Mouse | ELISA; FC |
To meet the high expectations of our customers for antibody quality, we have established a rigorous and comprehensive quality management system. By adhering to the strictest standards, we ensure the reliability and consistency of our products, providing researchers with dependable tools that support and accelerate scientific advancements.
Fig.1 SDS-PAGE analysis of anti-CLDN6 antibody
(Cat# TAB-510LC, Creative Biolabs).
Fig.2 SEC-HPLC analysis of anti-CLDN6 antibody
(Cat# TAB-510LC, Creative Biolabs).
Fig.3 Lectin ELISA analysis of anti-CLDN6 antibody
(Cat# AFC-160CL, Creative Biolabs).
With years of extensive experience in process optimization, we are dedicated to offering comprehensive solutions, from gene synthesis to antibody production. Serving as a trusted partner for biomedical researchers, we focus on delivering exceptional results to support and advance their critical research initiatives.
Featured Anti-CLDN6 Recombinant Antibody Production Platforms
Fig.4 Milligram-scale recombinant antibody production.
Fig.5 Gram-scale recombinant antibody production.
Creative Biolabs is fully committed to offering researchers high-quality recombinant antibodies in a wide variety of formats. Our goal is to cater to the unique and diverse needs of our customers. Recognizing the vital role that quality antibodies play in research, we strive to provide products that not only meet the highest standards but also come in convenient formats, ideal for different experimental setups.
Fig.6 Full LengthAnti-CLDN6 Recombinant Antibody Production and Modalities.
Table 1. Therapeutic approaches targeting CLDN6 in clinical development.
Research phase | Company | Classification | Indications | Details |
Phase I/II | BioNTech | Biologics | Cancer | This is a bispecific antibody targeting claudin-6 (CLDN6) and CD3, is in early clinical development at BioNTech for the treatment of CLDN-6-positive advanced solid tumors. |
Phase I/II | BioNTech | Biologics | Cancer | It is a CAR-T cell therapy targeting CLDN6 in early clinical development at BioNTech for the treatment of solid tumors. |
Phase I | TORL Biotherapeutics | Drug Conjugates | Cancer | This is an antibody-drug conjugate targeting the tumor specific antigen claudin 6 (CLDN6), is in early clinical development at TORL Biotherapeutics for the treatment of advanced solid tumors. |
Phase I | Chugai Pharmaceutical | Biologics | Cancer; Solid tumor | It is a trispecific antibody targeting CLDN6, CD3 and CD137 developed at Chugai Pharmaceutical in early phase clinical trials for the intravenous treatment of CLDN6-positive solid tumor. |
Phase I | Amgen | Biologics | Cancer | This is a bispecific T cell engager (BiTE) targeting claudin 6 (CLDN6) and CD3 in early clinical development at Amgen for the treatment of patients with locally advanced or metastatic malignant solid tumors, including non-squamous non-small cell lung cancer (NSCLC) and epithelial ovarian cancer. |
In case you require additional information about anti-CLDN6 recombinant antibody products, feel free to reach out to us. Our team is ready to provide you with the assistance you need, and we look forward to establishing a collaborative relationship that benefits both parties in advancing research efforts.